Marchand, Mathilde
326  Ergebnisse:
Personensuche X
?
1

Tumor growth and overall survival modeling to support decis..:

Marchand, Mathilde ; Gonçalves, Antonio ; Mercier, François...
CPT: Pharmacometrics & Systems Pharmacology.  13 (2024)  6 - p. 1017-1028 , 2024
 
?
3

Early Decision Making in a Randomized Phase II Trial of Ate..:

Shemesh, Colby S. ; Chan, Phyllis ; Marchand, Mathilde...
Clinical Pharmacology & Therapeutics.  114 (2023)  3 - p. 644-651 , 2023
 
?
4

Comparison of two‐stage and joint TGI‐OS modeling using dat..:

Gonçalves, Antonio ; Marchand, Mathilde ; Chan, Phyllis...
CPT: Pharmacometrics & Systems Pharmacology.  13 (2023)  1 - p. 68-78 , 2023
 
?
7

Extension of the Alternative Intravenous Dosing Regimens of..:

Liu, Stephanie N. ; Marchand, Mathilde ; Liu, Xiaoyan...
The Journal of Clinical Pharmacology.  62 (2022)  11 - p. 1393-1402 , 2022
 
?
9

Results of a Dose‐Finding Phase 1b Study of Subcutaneous At..:

Felip, Enriqueta ; Burotto, Mauricio ; Zvirbule, Zanete...
Clinical Pharmacology in Drug Development.  10 (2021)  10 - p. 1142-1155 , 2021
 
?
10

Time-dependent population PK models of single-agent atezoli..:

Marchand, Mathilde ; Zhang, Rong ; Chan, Phyllis...
Cancer Chemotherapy and Pharmacology.  88 (2021)  2 - p. 211-221 , 2021
 
?
11

Prediction of overall survival in patients across solid tum..:

Chan, Phyllis ; Marchand, Mathilde ; Yoshida, Kenta...
CPT: Pharmacometrics & Systems Pharmacology.  10 (2021)  10 - p. 1171-1182 , 2021
 
?
13

Alternative dosing regimens for atezolizumab: an example of..:

Morrissey, Kari M. ; Marchand, Mathilde ; Patel, Hina...
Cancer Chemotherapy and Pharmacology.  84 (2019)  6 - p. 1257-1267 , 2019
 
1-15